Trials
MRD trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Alliance for Clinical Trials in Oncology · 261 locations · Updated 2026-11-03
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines · 195 locations · Updated 2026-10-23
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines · 115 locations · Updated 2026-09-28
Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI
University of California, Irvine · 1 locations · Updated 2026-11-09
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Kerry Rogers · 1 locations · Updated 2026-11-09
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
City of Hope Medical Center · 2 locations · Updated 2026-11-06
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic · 3 locations · Updated 2026-10-26
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Fred Hutchinson Cancer Center · 1 locations · Updated 2026-10-23
Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Fred Hutchinson Cancer Center · 1 locations · Updated 2026-10-21
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Jennifer Woyach · 1 locations · Updated 2026-10-15
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
Stichting Hemato-Oncologie voor Volwassenen Nederland · 29 locations · Updated 2026-10-05
REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
Stichting Hemato-Oncologie voor Volwassenen Nederland · 18 locations · Updated 2026-09-21
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center · 1 locations · Updated 2026-09-10
Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
M.D. Anderson Cancer Center · 1 locations · Updated 2026-08-12
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Massachusetts General Hospital · 2 locations · Updated 2026-08-11
Pirtobrutinib+Sonrotoclax(PS) Regimen in the Treatment of B-Cell Lymphoma
Changzhou No.2 People's Hospital · 1 locations · Updated 2026-08-06
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
The Lymphoma Academic Research Organisation · 29 locations · Updated 2026-07-31
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Guangzhou Lupeng Pharmaceutical Company LTD. · 1 locations · Updated 2026-07-30
Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia
Medical College of Wisconsin · 1 locations · Updated 2026-07-08
Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL:Stop Trial 2.0
Yi Shuhua · 7 locations · Updated 2026-07-02
A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
The First Affiliated Hospital with Nanjing Medical University · 1 locations · Updated 2026-06-26
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota · 1 locations · Updated 2026-06-25
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
PETHEMA Foundation · 19 locations · Updated 2026-06-25
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Curis, Inc. · 11 locations · Updated 2026-06-12
Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).
French Innovative Leukemia Organisation · Locations not reported · Updated 2026-06-03
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
City of Hope Medical Center · 7 locations · Updated 2026-03-13
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center · 1 locations · Updated 2026-02-19
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Kerry Rogers · 1 locations · Updated 2026-02-19
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Jennifer R. Brown, MD, PhD · 1 locations · Updated 2026-02-11
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Zulfa Omer · 1 locations · Updated 2026-01-06
Mosunetuzumab for CLL MRD Clearance
Inhye Ahn · 2 locations · Updated 2025-12-15
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Dana-Farber Cancer Institute · 4 locations · Updated 2025-12-05
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
The First Affiliated Hospital with Nanjing Medical University · 1 locations · Updated 2025-11-25
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
The First Hospital of Jilin University · 1 locations · Updated 2025-06-04
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL
Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2024-04-16
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Paolo Ghia · 1 locations · Updated 2023-10-04
Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL
Paolo Ghia · 1 locations · Updated 2023-10-03
Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL
European Research Initiative on CLL · 1 locations · Updated 2026-08-19
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
OHSU Knight Cancer Institute · 1 locations · Updated 2025-11-06
Clinico-hematological and Molecular Characteristics of Chronic Lymphocytic Leukemia Patients
Assiut University · Locations not reported · Updated 2025-09-09
Showing 1–40 of 41. Older studies
More hematologic trials (21) that list MRD only as a secondary endpoint
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Merck Sharp & Dohme LLC · 107 locations · Updated 2026-11-17
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
German CLL Study Group · 30 locations · Updated 2026-08-20
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Ascentage Pharma Group Inc. · 10 locations · Updated 2026-07-28
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
VA Office of Research and Development · 4 locations · Updated 2026-10-30
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
AstraZeneca · 47 locations · Updated 2026-10-23
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Christine Ryan · 5 locations · Updated 2026-10-21
Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL
Dana-Farber Cancer Institute · 2 locations · Updated 2026-09-29
Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL
Institute of Hematology & Blood Diseases Hospital, China · 6 locations · Updated 2026-09-21
Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial
City of Hope Medical Center · 3 locations · Updated 2026-09-10
Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors
UNC Lineberger Comprehensive Cancer Center · 1 locations · Updated 2026-08-05
Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma
Henan Cancer Hospital · 1 locations · Updated 2026-07-29
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Beijing Biotech · 1 locations · Updated 2026-04-13
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
AbbVie · 58 locations · Updated 2026-02-09
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
Zulfa Omer · 1 locations · Updated 2026-01-06
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
Zulfa Omer · 1 locations · Updated 2025-08-14
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
John Lister · 1 locations · Updated 2025-01-13
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2019-06-10
CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia
Liping Dou · 1 locations · Updated 2026-10-27
CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia
Liping Dou · 1 locations · Updated 2026-10-02
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Mayo Clinic · 1 locations · Updated 2026-06-09
Precision Physical Exercise for Personalized Onco-Hematology.
University of Salamanca · Locations not reported · Updated 2025-12-16
Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.